This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

Altasciences adds capacity to support Phase III trials of Alladapt’s food allergy drug

Share this article

Services firm Altasciences is building a dedicated production unit for food-allergy focused medicine developer Alladapt Immunotherapeutics.

The manufacturing plant – which will be at Altasciences’ campus in Philadelphia – is designed to make supplies of ADP101 for Phase III clinical trials.

The new building, which is due to be operational next year, will also be used for commercial production if the drug is approved.

Altasciences will manage all aspects of this project, including warehousing, release management, manufacturing, quality assurance, and finished product release.

The new building will have additional client dedicated capacity that can be used for Phase I through to commercial manufacturing services.

Altasciences developed the formulation and manufacturing processes for phase I and II trials of ADP101, which is an oral therapy for children and adults who suffer food allergies.

Ben Reed, general manager, CDMO Services at Altasciences said, “we are pleased to continue supporting Alladapt in their important goal of developing a single therapeutic to address a wide range of mono- and multi-food allergies, and we look forward to fulfilling their Phase III and commercial requirements.”

Alladapt CEO Ashley Dombkowski cited Altasciences’ team as the foundation of the ongoing partnership.

“The training Altasciences provides their CDMO workforce is second to none, as each team member is well-equipped to optimize and complete our manufacturing projects.”

Expansion

Laval, Quebec-headquartered Altasciences has been expanding the Philadelphia site since December 2020 when it started work on additional warehousing capacity.

Reed framed Altasciences expansion program as part of an effort to offer pharmaceutical customers a wider range of formulation development, production, and storage services.

“Completing these significant expansions and investment into both capacity and state-of-the-art technology will ensure that Altasciences can provide the drug development solutions that our customers need now and in the future.”

Image: Stock Photo Secrets

Share this article

Sign up for Clinical Insider email updates